Key facts
- This page summarizes Rakhi Kumar's Form 4 filing for Roivant Sciences Ltd. (ROIV).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Feb 2025, 21:00.
Rakhi Kumar - 13 Feb 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)
- Reporting relationship
- Chief Accounting Officer
- Issuer ticker
- ROIV
- Reported as of
- 13 Feb 2025
- Net transaction value
- -$1,650,950
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2025, 21:00:26 UTC
- Prior SEC filing
- 22 Jan 2025
- Next SEC filing
- 24 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jo Chen, as Attorney-in-Fact for Rakhi Kumar
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rakhi Kumar filed Form 4 for Roivant Sciences Ltd. (ROIV) on 18 Feb 2025.
Change
- Previous filing in this sequence was filed on 22 Jan 2025.
- Current net transaction value: -$1,650,950.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $721,875
- Shares
- +187,500
- Change %
- +92%
- Price
- $3.85
- Shares after
- 390,764
- Date
- 13 Feb 2025
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $2,372,825
- Shares
- -227,500
- Change %
- -58%
- Price
- $10.43
- Shares after
- 163,264
- Date
- 13 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -187,500
- Change %
- -38%
- Price
- $0.000000
- Shares after
- 312,500
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 187,500
- Exercise price
- $3.85
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
Footnote F2
Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).